Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does not respond well to chemotherapy, when taking a combination of avutometinib and defactinib. The drugs work by blocking signals that encourage cancer cells to grow.

Scientists say the Royal Marsden hospitals' drug trial could change practice globally for serous form of ovarian cancer which doesn't respond well to chemotherapy

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy.

Women with difficult-to-treat ovarian cancer offered hope by new drugs - Professor Susana Banerjee, from the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research said the findings were ‘significant’.